Biotherapeutics.

Slides:

Advertisements

Similar presentations

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

Advertisements

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Introduction to Biosimilars

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Optimizing Use of Biological Agents in Ulcerative Colitis

Introduction/Background

Introducing JAK Inhibitors in Rheumatoid Arthritis

Understanding Biologics

Biosimilars in the Real World

Biosimilars in RA: A Blessing or a Curse?

Figure 3 Methods to detect trough levels of therapeutic antibodies

Treat to Target in Gout.

Applying Biosimilars in Oncology Practice: What Do You Need to Know?

Comparing Treatment Alternatives in Ankylosing Spondylitis

Optimizing Patient Outcomes in IBD

Chronic Idiopathic Urticaria

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Precision Management of RA and Comorbidities

Introduction. Family Planning and Pregnancy Management in Patients With Chronic Inflammatory Rheumatic Diseases.

Clinical Updates in RA: New Developments and Insights From Washington

Figure 3 Simplified EULAR and GRAPPA

HCV Protease Inhibitors in Clinical Practice

Case Collection in RA: Highlights of an Interactive Workshop

Is RA Treatment Addressing the Real Needs of Patients?

Next-Gen Psoriasis Therapies:

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Biosimilars in Hematologic Oncology

Evolving Treatment Landscape for PsA

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Advancing the Treatment of IBD With Biologics

When Is Biologic Therapy Appropriate for HS?

Figure 1 Simplified EULAR and GRAPPA

What's New in Therapeutic Options for Moderate to Severe RA?

Advancing Patient Care in RA

The Multifaceted Nature of Psoriasis Addressing Patients' Needs

Implications of Emerging Treatments for Beta-Thalassemia

Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges

The Rising Cost of Healthcare and Potential Impact of Biosimilars

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

HCV Protease Inhibitors in Clinical Practice

Severe Asthma and Comorbidities

How to Manage ISRs That Occur With Injectable Agents in Psoriasis

Critical Decision Points in Insomnia

Application of Biologics in IBD:

ADAb: anti-drug antibody.

Updates in RA, PsA, and Biosimilars

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Pathogenesis of IBD, and the Role of Biologic Therapies

AMD Therapy: Where Are We Now and Where Are We Going?

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Rheumatoid Arthritis.

Crohn’s Disease Biologic Pathway

EULAR Study Group: Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatology Aim of the study group To understand the required clinical and economic.

Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.

Classification Criteria for axSpA

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Treatment Advances for RA

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Biosimilars in Immune-Related Diseases

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Biotherapeutics

Introduction

Program Outline

Immunogenicity of Biologics in Chronic Inflammatory Diseases

Complex Nature of ADAs

Neutralizing and Non-Neutralizing Antibodies

Neutralizing and Non-Neutralizing Antibodies (Cont.)

Impact of ADAs

Factors Associated With Immunogenicity

MTX Reduces Immunogenicity in a Dose- Dependent Manner

Biologic Agent Monitoring in Daily Practice

Model: ADA Development and Decreased Biologic Serum Concentration

Biologic Agent Monitoring in Daily Practice

Measurement of Biologic Drug Serum Trough Concentration

Response to Targeted Treatment in RA

Potential Predictors of Response to Anti-TNF Treatment

Considerations for Patients With Loss of Response to Biologic Therapy

Reduction of Overexposure in Patients With RA and High Serum ADA Concentrations

RA Treatment Based on Antibody Responses?

Serum Drug Levels of Biologic Agents in the Management of RA: A Systematic Review

Potential Predictors of Response to Anti-TNF Treatment

EULAR Recommendations for the Management of RA With csDMARDs and bDMARDs

MTX Use in Patients With PsA or axSpA

Biosimilars and Their Reference Agents Are Interchangeable

The Data Requirements for Biosimilar Approval Are Comprehensive

NOR-SWITCH: Switching From Originator Infliximab to Biosimilar CT-P13

RCTs of Switching From Originator Infliximab to Biosimilar Infliximab in RA

Recommendations Regarding the Use of Biosimilars in Patients With RA

Use of Biosimilars: Discussion Points With Patients

Biosimilar Switching: Evidence From Arthritis Studies

Abbreviations

Abbreviations (cont)